Floatz logo

Teclistamab

Hematopoietic And Lymphoid System Neoplasm

Janssen Pharmaceutical K.K.monoclonal_antibodyPhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

133 Active assets in the Hematopoietic And Lymphoid System Neoplasm cohort.

Asset / SponsorPhaseRating
Adriamycin
OHSU Knight Cancer Institute
Phase 4BBB
Dexasone
City of Hope Medical Center
Phase 3BB
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 3BB
Bortezomib
OHSU Knight Cancer Institute
Phase 4BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Teclistamab is also rated in:

plasma cell myelomaActive
BB
Indicative · Phase 4
67 / 100
View asset →
Waldenstrom macroglobulinemiaActive
BB
Indicative · Phase 4
65 / 100
View asset →
plasma cell leukemiaActive
B
Indicative · Phase 3
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →